+关注
Potatoe
暂无个人介绍
IP属地：未知
11
关注
1
粉丝
0
主题
0
勋章
主贴
热门
Potatoe
2021-11-03
Cool
抱歉，原内容已删除
Potatoe
2021-10-24
Cool
Intel: Good Value Or Value Trap?
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3570707553717428,"uuid":"3570707553717428","gmtCreate":1607767911477,"gmtModify":1615256268168,"name":"Potatoe","pinyin":"potatoe","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/cc3bd60b439769a7211eb0b3a1415aef","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":11,"tweetSize":38,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.65%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":841446035,"gmtCreate":1635938119777,"gmtModify":1635938579224,"author":{"id":"3570707553717428","authorId":"3570707553717428","name":"Potatoe","avatar":"https://static.tigerbbs.com/cc3bd60b439769a7211eb0b3a1415aef","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841446035","repostId":"2180756854","repostType":4,"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":858649269,"gmtCreate":1635048563388,"gmtModify":1635048563481,"author":{"id":"3570707553717428","authorId":"3570707553717428","name":"Potatoe","avatar":"https://static.tigerbbs.com/cc3bd60b439769a7211eb0b3a1415aef","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/858649269","repostId":"1100055241","repostType":4,"repost":{"id":"1100055241","pubTimestamp":1635040192,"share":"https://www.laohu8.com/m/news/1100055241?lang=&edition=full","pubTime":"2021-10-24 09:49","market":"us","language":"en","title":"Intel: Good Value Or Value Trap?","url":"https://stock-news.laohu8.com/highlight/detail?id=1100055241","media":"Seeking Alpha","summary":"Intel had a mixed earnings report that sent some investors running for the hills.The company beat earnings and actually raised guidance for 2021, but they signaled that supply chain issues remain and profitability in 2022 will be lower.After the sell-off, is Intel a good value or a value trap?The waters have been pretty rough for Intel Corp. investors over the past few years.It seems like every time the sun comes out...there is another storm right around the corner.As highlighted on the earning","content":"<p><b>Summary</b></p>\n<ul>\n <li>Intel had a mixed earnings report that sent some investors running for the hills.</li>\n <li>The company beat earnings and actually raised guidance for 2021, but they signaled that supply chain issues remain and profitability in 2022 will be lower.</li>\n <li>After the sell-off, is Intel a good value or a value trap?</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c02609041d90c055d66b217f06706d28\" tg-width=\"1536\" tg-height=\"1022\" referrerpolicy=\"no-referrer\"><span>4kodiak/iStock Unreleased via Getty Images</span></p>\n<p>The waters have been pretty rough for Intel Corp. (INTC) investors over the past few years.</p>\n<p>It seems like every time the sun comes out...there is another storm right around the corner.</p>\n<p>As highlighted on the earnings call last night, the next \"storm\" brewing for Intel is continued supply chain issues (component shortages in the PC business) and reduced near-term profitability from rising capital expenditure needs, which has sent the stock plummeting 11% this morning into the abyss.</p>\n<p><img src=\"https://static.tigerbbs.com/5bd612f6f25b6e86d7a72b38440d513f\" tg-width=\"640\" tg-height=\"449\" referrerpolicy=\"no-referrer\"></p>\n<p>However, buying the dips has actually been pretty lucrative in the recent past...if, of course, you were lucky enough to fade the rallies.</p>\n<p>To be fair, Intel has had its fair share of challenges this year, despite general tailwinds in the industry (i.e., chip demand far outpacing supply).</p>\n<p>Specifically, Intel has had some well-documented manufacturing blunders that have caused major delays and loss of some market share...mainly to Advanced Micro Devices (AMD).</p>\n<p>This has triggered concern amongst investors that the stock may be a potential \"value trap\" now.</p>\n<p>All that said, Intel is dedicated to spending $25 billion to $28 billion in 2022 and just broke ground on some new fabs.</p>\n<p>Personally, I don't think we are anywhere near peak demand for chips and I believe that Intel's fabrication capabilities are (and will continue to be) a huge advantage for the company for years to come.</p>\n<p>So how can we structure a trade to take advantage of the upside potential in the stock (after this pullback) while also protecting ourselves from more near-term downside (if any)?</p>\n<p><b>It's a perfect situation for a \"Triple Play\" trade!</b></p>\n<p>Intel Corp.</p>\n<p><b>Sector/Industry:</b>Technology/Semiconductors</p>\n<blockquote>\n Intel is the world's largest chipmaker. It designs and manufactures microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors. It was the prime proponent of Moore's Law for advances in semiconductor manufacturing, though the firm has recently faced manufacturing delays. While Intel's server processor business has benefited from the shift to the cloud, the firm has also been expanding into new adjacencies as the personal computer market has stagnated. These include areas such as the Internet of Things, artificial intelligence, and automotive. Intel has been active on the merger and acquisitions front, acquiring Altera, Mobileye, and Habana Labs in order to bolster these efforts in non-PC arenas.\n</blockquote>\n<p><i>Source: YCharts</i></p>\n<p><b>Valuation/Upside Potential</b></p>\n<p>Intel looks extremely attractive from a valuation standpoint and is currently trading at a decent discount to all of its long-term valuation metrics (hence the high Value Ranking of 10).</p>\n<p>Specifically, Intel is trading at a nice discount to its historical P/E multiple on a forward basis (10.6x 2021 earnings).<i>Note that the company actually just increased its guidance for fiscal 2021 earnings to $5.28 per share</i>.</p>\n<p>That said, as supply chain worries decrease over time, we definitely think there could be some room for margin expansion in the future.</p>\n<p>If you put just a 12x-14x multiple on consensus forward earnings of $5.28 per share for FYE 2021, that would equate to a $63.00- $73.00 stock price (representing 25%-45% upside from current levels).</p>\n<p>Although it probably won't get there in a straight line...</p>\n<p><b>\"Triple Play\" Trade Analysis</b></p>\n<p>A \"Triple Play\" trade involves simultaneously selling a cash-secured put and a covered call on a stock that you own.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7e3af23e0208929d569a6e62a12a9607\" tg-width=\"640\" tg-height=\"360\" referrerpolicy=\"no-referrer\"><span>Source: Option Income Advisor</span></p>\n<p>Note that if you don't currently own INTC stock, you will want to buy it before you write the covered call.</p>\n<p>This trade will allow you to take advantage of the upside potential in the stock while also protecting some of the near-term downside (if any).</p>\n<p><b>Step 1: Sell Cash-Secured Puts (50% of position size)</b></p>\n<p>The first step of the Triple Play trade is to sell a cash-secured put on the stock for 50% of your target position size. For example, if you wanted to own 400 shares of INTC... you would sell 2 cash-secured put contract, which represents 200 shares of stock.</p>\n<p>The three main data points we look at when analyzing a cash-secured put trade are:</p>\n<ul>\n <li>Premium Yield % (or Average Monthly Yield %): Measure of expected return on capital assuming that the option expires worthless (out-of-the-money).<i>Assumes that the option is fully cash secured.</i></li>\n <li>Margin-of-Safety %: Measure of downside protection or the percentage that the underlying stock could decline and would still allow you to break even on the option trade.</li>\n <li>Delta: A good proxy for the probability that the put option will finish in-the-money.</li>\n</ul>\n<p><i>Note that there's always a negative correlation between Premium Yield and Margin of Safety: The higher the Premium Yield for a given strike month, the lower the Margin of Safety.</i></p>\n<p><i>Investors always should be honest with themselves about their risk tolerance. Selling CSPs can be adapted to suit your needs.</i></p>\n<p>As discussed in the video, we like the $45.00-$50.00 range for INTC in the near term. So we like the following cash-secured put:</p>\n<p><i><b>INTC Nov 19th $47.50.00 Put (28 days until expiration)</b></i></p>\n<ul>\n <li>Option Premium: ~$0.58 premium</li>\n <li>Average Monthly Yield %: 1.3% (15.6% annualized)</li>\n <li>Margin-of-Safety %: 4.2%</li>\n <li>Delta: 28</li>\n</ul>\n<p><b>Step 2: Buy the Stock (50% of position size)</b></p>\n<p><i>Note: At the time of publication, INTC was trading at $49.60. If you already own the stock, you can skip to Step 3.</i></p>\n<p>The second step of the Triple Play is to buy the stock (50% of your target position size). For example, if you wanted to own 400 shares of INTC... you would buy 200 shares of stock.</p>\n<p><b>Step 3: Sell Covered Calls On Your Stock Position (*optional*)</b></p>\n<p>A covered call strategy will help generate some short-term income, maintain some upside exposure, and mitigate some downside risk.</p>\n<p>With a covered call, you are agreeing to sell your stock at a higher price (your call option strike price) but you get to keep your call option premium either way.</p>\n<p>As discussed in the video, since we like the upside potential in the near term with INTC, you will want to give yourself some room for the stock to run.<b>So we would actually recommend waiting for the stock to trade a little higher before selling covered calls.</b></p>\n<p>That said, if you wanted to execute the covered calls today, I would certainly consider taking less premium income to preserve more potential upside profit. For example, the $53.00 call would give you an extra 0.5% of income per month (6.0% annualized)...which would essentially triple your dividend yield on the stock!</p>\n<p><i><b>INTC Nov 19th $53.00 Call (28 days until expiration)</b></i></p>\n<ul>\n <li>Option Premium: ~$0.25 premium</li>\n <li>Average Monthly Yield %: 0.5% (6.0% annualized)</li>\n <li>Upside Profit %: 7.4%</li>\n <li>Delta: 15</li>\n</ul>\n<p><b>Conclusion</b></p>\n<p>This Triple Play trade will allow you to take advantage of the upside potential in INTC stock while also giving you some downside cushion if shares trade lower in the near term. As the covered calls and cash-secured puts expire, you can rinse and repeat the Triple Play trade!</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel: Good Value Or Value Trap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel: Good Value Or Value Trap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-24 09:49 GMT+8 <a href=https://seekingalpha.com/article/4461530-intel-intc-stock-good-value-or-value-trap><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nIntel had a mixed earnings report that sent some investors running for the hills.\nThe company beat earnings and actually raised guidance for 2021, but they signaled that supply chain issues ...</p>\n\n<a href=\"https://seekingalpha.com/article/4461530-intel-intc-stock-good-value-or-value-trap\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"source_url":"https://seekingalpha.com/article/4461530-intel-intc-stock-good-value-or-value-trap","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100055241","content_text":"Summary\n\nIntel had a mixed earnings report that sent some investors running for the hills.\nThe company beat earnings and actually raised guidance for 2021, but they signaled that supply chain issues remain and profitability in 2022 will be lower.\nAfter the sell-off, is Intel a good value or a value trap?\n\n4kodiak/iStock Unreleased via Getty Images\nThe waters have been pretty rough for Intel Corp. (INTC) investors over the past few years.\nIt seems like every time the sun comes out...there is another storm right around the corner.\nAs highlighted on the earnings call last night, the next \"storm\" brewing for Intel is continued supply chain issues (component shortages in the PC business) and reduced near-term profitability from rising capital expenditure needs, which has sent the stock plummeting 11% this morning into the abyss.\n\nHowever, buying the dips has actually been pretty lucrative in the recent past...if, of course, you were lucky enough to fade the rallies.\nTo be fair, Intel has had its fair share of challenges this year, despite general tailwinds in the industry (i.e., chip demand far outpacing supply).\nSpecifically, Intel has had some well-documented manufacturing blunders that have caused major delays and loss of some market share...mainly to Advanced Micro Devices (AMD).\nThis has triggered concern amongst investors that the stock may be a potential \"value trap\" now.\nAll that said, Intel is dedicated to spending $25 billion to $28 billion in 2022 and just broke ground on some new fabs.\nPersonally, I don't think we are anywhere near peak demand for chips and I believe that Intel's fabrication capabilities are (and will continue to be) a huge advantage for the company for years to come.\nSo how can we structure a trade to take advantage of the upside potential in the stock (after this pullback) while also protecting ourselves from more near-term downside (if any)?\nIt's a perfect situation for a \"Triple Play\" trade!\nIntel Corp.\nSector/Industry:Technology/Semiconductors\n\n Intel is the world's largest chipmaker. It designs and manufactures microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors. It was the prime proponent of Moore's Law for advances in semiconductor manufacturing, though the firm has recently faced manufacturing delays. While Intel's server processor business has benefited from the shift to the cloud, the firm has also been expanding into new adjacencies as the personal computer market has stagnated. These include areas such as the Internet of Things, artificial intelligence, and automotive. Intel has been active on the merger and acquisitions front, acquiring Altera, Mobileye, and Habana Labs in order to bolster these efforts in non-PC arenas.\n\nSource: YCharts\nValuation/Upside Potential\nIntel looks extremely attractive from a valuation standpoint and is currently trading at a decent discount to all of its long-term valuation metrics (hence the high Value Ranking of 10).\nSpecifically, Intel is trading at a nice discount to its historical P/E multiple on a forward basis (10.6x 2021 earnings).Note that the company actually just increased its guidance for fiscal 2021 earnings to $5.28 per share.\nThat said, as supply chain worries decrease over time, we definitely think there could be some room for margin expansion in the future.\nIf you put just a 12x-14x multiple on consensus forward earnings of $5.28 per share for FYE 2021, that would equate to a $63.00- $73.00 stock price (representing 25%-45% upside from current levels).\nAlthough it probably won't get there in a straight line...\n\"Triple Play\" Trade Analysis\nA \"Triple Play\" trade involves simultaneously selling a cash-secured put and a covered call on a stock that you own.\nSource: Option Income Advisor\nNote that if you don't currently own INTC stock, you will want to buy it before you write the covered call.\nThis trade will allow you to take advantage of the upside potential in the stock while also protecting some of the near-term downside (if any).\nStep 1: Sell Cash-Secured Puts (50% of position size)\nThe first step of the Triple Play trade is to sell a cash-secured put on the stock for 50% of your target position size. For example, if you wanted to own 400 shares of INTC... you would sell 2 cash-secured put contract, which represents 200 shares of stock.\nThe three main data points we look at when analyzing a cash-secured put trade are:\n\nPremium Yield % (or Average Monthly Yield %): Measure of expected return on capital assuming that the option expires worthless (out-of-the-money).Assumes that the option is fully cash secured.\nMargin-of-Safety %: Measure of downside protection or the percentage that the underlying stock could decline and would still allow you to break even on the option trade.\nDelta: A good proxy for the probability that the put option will finish in-the-money.\n\nNote that there's always a negative correlation between Premium Yield and Margin of Safety: The higher the Premium Yield for a given strike month, the lower the Margin of Safety.\nInvestors always should be honest with themselves about their risk tolerance. Selling CSPs can be adapted to suit your needs.\nAs discussed in the video, we like the $45.00-$50.00 range for INTC in the near term. So we like the following cash-secured put:\nINTC Nov 19th $47.50.00 Put (28 days until expiration)\n\nOption Premium: ~$0.58 premium\nAverage Monthly Yield %: 1.3% (15.6% annualized)\nMargin-of-Safety %: 4.2%\nDelta: 28\n\nStep 2: Buy the Stock (50% of position size)\nNote: At the time of publication, INTC was trading at $49.60. If you already own the stock, you can skip to Step 3.\nThe second step of the Triple Play is to buy the stock (50% of your target position size). For example, if you wanted to own 400 shares of INTC... you would buy 200 shares of stock.\nStep 3: Sell Covered Calls On Your Stock Position (*optional*)\nA covered call strategy will help generate some short-term income, maintain some upside exposure, and mitigate some downside risk.\nWith a covered call, you are agreeing to sell your stock at a higher price (your call option strike price) but you get to keep your call option premium either way.\nAs discussed in the video, since we like the upside potential in the near term with INTC, you will want to give yourself some room for the stock to run.So we would actually recommend waiting for the stock to trade a little higher before selling covered calls.\nThat said, if you wanted to execute the covered calls today, I would certainly consider taking less premium income to preserve more potential upside profit. For example, the $53.00 call would give you an extra 0.5% of income per month (6.0% annualized)...which would essentially triple your dividend yield on the stock!\nINTC Nov 19th $53.00 Call (28 days until expiration)\n\nOption Premium: ~$0.25 premium\nAverage Monthly Yield %: 0.5% (6.0% annualized)\nUpside Profit %: 7.4%\nDelta: 15\n\nConclusion\nThis Triple Play trade will allow you to take advantage of the upside potential in INTC stock while also giving you some downside cushion if shares trade lower in the near term. As the covered calls and cash-secured puts expire, you can rinse and repeat the Triple Play trade!","news_type":1},"isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":858649269,"gmtCreate":1635048563388,"gmtModify":1635048563481,"author":{"id":"3570707553717428","authorId":"3570707553717428","name":"Potatoe","avatar":"https://static.tigerbbs.com/cc3bd60b439769a7211eb0b3a1415aef","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/858649269","repostId":"1100055241","repostType":4,"isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841446035,"gmtCreate":1635938119777,"gmtModify":1635938579224,"author":{"id":"3570707553717428","authorId":"3570707553717428","name":"Potatoe","avatar":"https://static.tigerbbs.com/cc3bd60b439769a7211eb0b3a1415aef","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841446035","repostId":"2180756854","repostType":4,"repost":{"id":"2180756854","pubTimestamp":1635936367,"share":"https://www.laohu8.com/m/news/2180756854?lang=&edition=full","pubTime":"2021-11-03 18:46","market":"us","language":"en","title":"5 Biotech Stocks With 105% to 386% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2180756854","media":"Motley Fool","summary":"Since the Great Recession ended more than 12 years ago, innovative, high-growth companies have ruled","content":"<p>Since the Great Recession ended more than 12 years ago, innovative, high-growth companies have ruled the roost on Wall Street. Historically low lending rates and an abundance of cheap capital have allowed fast-paced companies to borrow in order to hire, acquire, and innovate.</p>\n<p>But even after a monster rally in equities, Wall Street still sees significant upside in a handful of companies. In particular, biotech stocks have the attention of select analysts and investment banks.</p>\n<p>Based on the high-water price target issued by analysts or investment banks, the following five biotech offer upside ranging from 105% to as much as 386% over the next 12 months.</p>\n<h2>Novavax: Implied upside of 105%</h2>\n<p>Arguably the best-known biotech stock on this list is clinical-stage drug developer <b>Novavax</b> (NASDAQ:NVAX). Novavax, which is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of a small number of companies developing a coronavirus disease 2019 (COVID-19) vaccine, is projected to hit $305 a share, according to analyst Mayank Mamtani at B. Riley. If Mamtani's 12-month price target is accurate, Novavax would more than double.</p>\n<p>In terms of vaccine efficacy (VE), there's plenty of momentum in Novavax's sails. The company has run two extensive late-stage studies in the U.K. and the U.S./Mexico, which respectively yielded VE's of 89.7% and 90.4%. Although VE is just one of numerous important metrics in terms of vaccine effectiveness, this roughly 90% VE should be enough to allow NVX-CoV2373, Novavax's COVID-19 vaccine, to leapfrog <b>Johnson & Johnson</b> and <b>AstraZeneca</b> on the vaccine front.</p>\n<p>The biggest issue for Novavax has been executing beyond the lab. New drug application filings in developed markets have been delayed, and there are now concerns about the purity level of its manufactured vaccine. Though these errors are costing Novavax some easy short-term revenue potential, there are billions of inoculations yet to be administered. Considering how inexpensive Novavax is relative to other COVID-19 vaccine producers, a $305 price target isn't out of the question.</p>\n<h2>Ligand Pharmaceuticals: Implied upside of 112%</h2>\n<p>Next up is <b>Ligand Pharmaceuticals</b> (NASDAQ:LGND), which is part biotech company and part development platform. According to projections from H.C. Wainwright analyst Joseph Pantginis, Ligand could hit $310 a share over the next year. This implies upside of 112%.</p>\n<p>Unlike traditional biotech stocks that see drugs from the discovery stage through clinical development, Ligand primarily focuses on licensing its intellectual property (IP), which includes drug development platforms and/or early stage compounds. There's a lot less risk involved with licensing out its technology because it gives Ligand a greater chance of diversifying its revenue stream. Instead of being reliant on a couple of drugs with a finite period of exclusivity, Ligand has seen approximately 80 new clinical-stage programs utilizing its OmniAb platform start this year alone.</p>\n<p>The downside of Ligand's royalty-based portfolio is that revenue recognition can be lumpy at times, especially when milestone payouts are mixed in. Ligand also finds itself at risk of losing royalty revenue when exclusivity periods end. This means quite a bit of Ligand's growth has been based on acquisitions, which can raise short-term costs.</p>\n<p>Already valued at a multiple of roughly 36 times forward-year earnings, it's tough to envision Ligand's share price heading significantly higher.</p>\n<h2>CRISPR Therapeutics: Implied upside of 141%</h2>\n<p>Another big-name clinical-stage biotech stock with some serious upside potential is <b>CRISPR Therapeutics</b> (NASDAQ:CRSP). Of the more than one dozen investment banks covering CRISPR, the Wall Street high calls for $220 a share. A move to $220 from where it closed this past weekend ($91.33) would entail 141% upside for its shareholders.</p>\n<p>The excitement surrounding CRISPR has to do with its approach of using gene-editing technology to alter genomic DNA in order to tackle hard-to-treat diseases. What gives validity to this approach is the partnership CRISPR landed with <b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX), which itself has a rich history of developing blockbuster drugs for hard-to-treat diseases. The duo are developing CTX001 as a treatment for transfusion-dependent beta thalassemia and sickle cell disease. CRISPR received a $900 million collaboration payment from Vertex during the second quarter.</p>\n<p>As my Foolish colleague Alex Carchidi recently pointed out, CRISPR is also involved in the development of off-the-shelf immunotherapies that could greatly speed up treatment for patients with multiple myeloma and blood cancers.</p>\n<p>However, it should be noted that CRISPR's treatments, while encouraging, are all relatively early in their development process. It'll likely be some time before investors know whether a $220 price target is reasonable or achievable.</p>\n<h2>Vaxart: Implied upside of 168%</h2>\n<p>Small-cap clinical-stage biotech stock <b>Vaxart</b> (NASDAQ:VXRT) might also have a lot of room to run, if Wall Street is correct. Analyst Yasmeen Rahimi of Piper Sandler currently has the high-water price target on Vaxart of $18. If Rahimi is correct, Vaxart's share price could climb 168% over the coming 12 months.</p>\n<p>What makes Vaxart so unique is its approach to tackling the COVID-19 pandemic. It's one of only a very small number of global drug developers working on an oral COVID-19 treatment. In fact, on Oct. 26, the company announced that the first patient in its phase 2 study involving VXA-CoV2-1.1-S had been dosed (don't these drug names roll off the tongue?). Vaxart's Vector-Adjuvant-Antigen Standardized Technology (VAAST) platform is designed to create oral treatments that can activate systemic <i>and</i> mucosal immunity, which should give patients better odds of fighting back against targeted viruses.</p>\n<p>The concern is that VXA-CoV2-1, which was targeted at the nucleoprotein (N) and spike protein (S) of COVID-19, didn't perform all that well in early stage clinical trials. Despite inducing a clear immune response in trial participants, high levels of neutralizing antibodies weren't present. High levels of neutralizing antibodies have been witnessed following traditional COVID-19 vaccines.</p>\n<p>Vaxart's phase 2 trial specifically targets the S protein, which the company believes will produce more favorable results. Nevertheless, we're likely a ways away from knowing whether a viable oral treatment can be developed for COVID-19.</p>\n<h2><a href=\"https://laohu8.com/S/ICPT\">Intercept Pharmaceuticals</a>: Implied upside of 386%</h2>\n<p>However, the crème-de-la-crème of upside opportunity among biotech stocks on this list is small-cap liver disease-focused drugmaker <b>Intercept Pharmaceuticals</b> (NASDAQ:ICPT). Piper Sandler's Rahimi is the most bullish here, as well, with a price target of $82. Considering that Intercept closed out the previous week at less than $17 a share, it implies an increase of 386% over the next year.</p>\n<p>Fueling Rahimi's optimism is the company's most-promising treatment, obeticholic acid (OCA). OCA is designed as a treatment for nonalcoholic steatohepatitis (NASH), which is a liver disease that affects 2% to 5% of U.S. adults and can lead to fibrosis, cancer, and even death. There's no cure or approved treatments for this potential $35 billion market.</p>\n<p>The good news for Intercept is OCA met one of its co-primary endpoints in the late-stage Regenerate trial -- a statistically significant reduction in fibrosis without a worsening of NASH. The bad news is this still wasn't enough for the Food and Drug Administration to give OCA the green light. With additional safety data being gathered, the expectation is that Intercept will (again) seek approval in 2022.</p>\n<p>Even with the highest dose of OCA leading to a significant uptick in bouts of pruritus during the Regenerate trial, relative to the placebo, this drug could prove useful for certain subsets of NASH patients. If Intercept gains approval, $82 could be an eventual realistic price target. Hitting $82 over the next year, though, is asking a bit much.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Biotech Stocks With 105% to 386% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Biotech Stocks With 105% to 386% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 18:46 GMT+8 <a href=https://www.fool.com/investing/2021/11/03/5-biotech-stocks-105-to-386-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since the Great Recession ended more than 12 years ago, innovative, high-growth companies have ruled the roost on Wall Street. Historically low lending rates and an abundance of cheap capital have ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/03/5-biotech-stocks-105-to-386-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRSP":"CRISPR Therapeutics AG","LGND":"Ligand Pharmaceuticals Inc.","NVAX":"诺瓦瓦克斯医药","VXRT":"Vaxart, Inc","ICPT":"Intercept Pharmaceuticals"},"source_url":"https://www.fool.com/investing/2021/11/03/5-biotech-stocks-105-to-386-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180756854","content_text":"Since the Great Recession ended more than 12 years ago, innovative, high-growth companies have ruled the roost on Wall Street. Historically low lending rates and an abundance of cheap capital have allowed fast-paced companies to borrow in order to hire, acquire, and innovate.\nBut even after a monster rally in equities, Wall Street still sees significant upside in a handful of companies. In particular, biotech stocks have the attention of select analysts and investment banks.\nBased on the high-water price target issued by analysts or investment banks, the following five biotech offer upside ranging from 105% to as much as 386% over the next 12 months.\nNovavax: Implied upside of 105%\nArguably the best-known biotech stock on this list is clinical-stage drug developer Novavax (NASDAQ:NVAX). Novavax, which is one of a small number of companies developing a coronavirus disease 2019 (COVID-19) vaccine, is projected to hit $305 a share, according to analyst Mayank Mamtani at B. Riley. If Mamtani's 12-month price target is accurate, Novavax would more than double.\nIn terms of vaccine efficacy (VE), there's plenty of momentum in Novavax's sails. The company has run two extensive late-stage studies in the U.K. and the U.S./Mexico, which respectively yielded VE's of 89.7% and 90.4%. Although VE is just one of numerous important metrics in terms of vaccine effectiveness, this roughly 90% VE should be enough to allow NVX-CoV2373, Novavax's COVID-19 vaccine, to leapfrog Johnson & Johnson and AstraZeneca on the vaccine front.\nThe biggest issue for Novavax has been executing beyond the lab. New drug application filings in developed markets have been delayed, and there are now concerns about the purity level of its manufactured vaccine. Though these errors are costing Novavax some easy short-term revenue potential, there are billions of inoculations yet to be administered. Considering how inexpensive Novavax is relative to other COVID-19 vaccine producers, a $305 price target isn't out of the question.\nLigand Pharmaceuticals: Implied upside of 112%\nNext up is Ligand Pharmaceuticals (NASDAQ:LGND), which is part biotech company and part development platform. According to projections from H.C. Wainwright analyst Joseph Pantginis, Ligand could hit $310 a share over the next year. This implies upside of 112%.\nUnlike traditional biotech stocks that see drugs from the discovery stage through clinical development, Ligand primarily focuses on licensing its intellectual property (IP), which includes drug development platforms and/or early stage compounds. There's a lot less risk involved with licensing out its technology because it gives Ligand a greater chance of diversifying its revenue stream. Instead of being reliant on a couple of drugs with a finite period of exclusivity, Ligand has seen approximately 80 new clinical-stage programs utilizing its OmniAb platform start this year alone.\nThe downside of Ligand's royalty-based portfolio is that revenue recognition can be lumpy at times, especially when milestone payouts are mixed in. Ligand also finds itself at risk of losing royalty revenue when exclusivity periods end. This means quite a bit of Ligand's growth has been based on acquisitions, which can raise short-term costs.\nAlready valued at a multiple of roughly 36 times forward-year earnings, it's tough to envision Ligand's share price heading significantly higher.\nCRISPR Therapeutics: Implied upside of 141%\nAnother big-name clinical-stage biotech stock with some serious upside potential is CRISPR Therapeutics (NASDAQ:CRSP). Of the more than one dozen investment banks covering CRISPR, the Wall Street high calls for $220 a share. A move to $220 from where it closed this past weekend ($91.33) would entail 141% upside for its shareholders.\nThe excitement surrounding CRISPR has to do with its approach of using gene-editing technology to alter genomic DNA in order to tackle hard-to-treat diseases. What gives validity to this approach is the partnership CRISPR landed with Vertex Pharmaceuticals (NASDAQ:VRTX), which itself has a rich history of developing blockbuster drugs for hard-to-treat diseases. The duo are developing CTX001 as a treatment for transfusion-dependent beta thalassemia and sickle cell disease. CRISPR received a $900 million collaboration payment from Vertex during the second quarter.\nAs my Foolish colleague Alex Carchidi recently pointed out, CRISPR is also involved in the development of off-the-shelf immunotherapies that could greatly speed up treatment for patients with multiple myeloma and blood cancers.\nHowever, it should be noted that CRISPR's treatments, while encouraging, are all relatively early in their development process. It'll likely be some time before investors know whether a $220 price target is reasonable or achievable.\nVaxart: Implied upside of 168%\nSmall-cap clinical-stage biotech stock Vaxart (NASDAQ:VXRT) might also have a lot of room to run, if Wall Street is correct. Analyst Yasmeen Rahimi of Piper Sandler currently has the high-water price target on Vaxart of $18. If Rahimi is correct, Vaxart's share price could climb 168% over the coming 12 months.\nWhat makes Vaxart so unique is its approach to tackling the COVID-19 pandemic. It's one of only a very small number of global drug developers working on an oral COVID-19 treatment. In fact, on Oct. 26, the company announced that the first patient in its phase 2 study involving VXA-CoV2-1.1-S had been dosed (don't these drug names roll off the tongue?). Vaxart's Vector-Adjuvant-Antigen Standardized Technology (VAAST) platform is designed to create oral treatments that can activate systemic and mucosal immunity, which should give patients better odds of fighting back against targeted viruses.\nThe concern is that VXA-CoV2-1, which was targeted at the nucleoprotein (N) and spike protein (S) of COVID-19, didn't perform all that well in early stage clinical trials. Despite inducing a clear immune response in trial participants, high levels of neutralizing antibodies weren't present. High levels of neutralizing antibodies have been witnessed following traditional COVID-19 vaccines.\nVaxart's phase 2 trial specifically targets the S protein, which the company believes will produce more favorable results. Nevertheless, we're likely a ways away from knowing whether a viable oral treatment can be developed for COVID-19.\nIntercept Pharmaceuticals: Implied upside of 386%\nHowever, the crème-de-la-crème of upside opportunity among biotech stocks on this list is small-cap liver disease-focused drugmaker Intercept Pharmaceuticals (NASDAQ:ICPT). Piper Sandler's Rahimi is the most bullish here, as well, with a price target of $82. Considering that Intercept closed out the previous week at less than $17 a share, it implies an increase of 386% over the next year.\nFueling Rahimi's optimism is the company's most-promising treatment, obeticholic acid (OCA). OCA is designed as a treatment for nonalcoholic steatohepatitis (NASH), which is a liver disease that affects 2% to 5% of U.S. adults and can lead to fibrosis, cancer, and even death. There's no cure or approved treatments for this potential $35 billion market.\nThe good news for Intercept is OCA met one of its co-primary endpoints in the late-stage Regenerate trial -- a statistically significant reduction in fibrosis without a worsening of NASH. The bad news is this still wasn't enough for the Food and Drug Administration to give OCA the green light. With additional safety data being gathered, the expectation is that Intercept will (again) seek approval in 2022.\nEven with the highest dose of OCA leading to a significant uptick in bouts of pruritus during the Regenerate trial, relative to the placebo, this drug could prove useful for certain subsets of NASH patients. If Intercept gains approval, $82 could be an eventual realistic price target. Hitting $82 over the next year, though, is asking a bit much.","news_type":1},"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
